Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from NATCO Pharma Limited ( (IN:NATCOPHARM) ).
Natco Pharma Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2025. This certificate confirms that securities received for dematerialization have been processed correctly, with updates made to the depositories’ records, ensuring compliance with regulatory requirements. This announcement underscores Natco Pharma’s commitment to maintaining regulatory compliance and transparency in its operations, which is crucial for its stakeholders and market reputation.
More about NATCO Pharma Limited
Natco Pharma Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of generic drugs and specialty pharmaceuticals. The company is known for its strong presence in the Indian market and its efforts to expand internationally.
Average Trading Volume: 61,410
Technical Sentiment Signal: Sell
Current Market Cap: 145.3B INR
Learn more about NATCOPHARM stock on TipRanks’ Stock Analysis page.